

|   |  |  |  |                            |  |                   |  |
|---|--|--|--|----------------------------|--|-------------------|--|
| <b>FORM PTO-1449</b>                    |  |  |  | <b>SERIAL NO.</b>          |  | 10/587,823        |  |
| <b>INFORMATION DISCLOSURE STATEMENT</b> |  |  |  | <b>FILING DATE</b>         |  | December 20, 2006 |  |
|   |  |  |  | <b>APPLICANT</b>           |  | Mercep et al.     |  |
|   |  |  |  | <b>GROUP</b>               |  | 1624              |  |
|   |  |  |  | <b>EXAMINER</b>            |  | N.E. Jarrell      |  |
|   |  |  |  | <b>ATTORNEY DOCKET NO.</b> |  | PLP537USW         |  |

  

| U.S. PATENT DOCUMENTS  |   |               |                |                   |       |          |                            |
|------------------------|---|---------------|----------------|-------------------|-------|----------|----------------------------|
| Examiner Initials      |   | Patent Number | Issue Date     | Name              | Class | Subclass | Filing Date If Appropriate |
|                        | 1 | 3,711,489     | Jan., 16, 1973 | Lombardino        |       |          |                            |
|                        | 2 | 3,894,032     | July 8, 1975   | Remy              |       |          |                            |
|                        | 3 | 3,974,285     | Aug. 10, 1976  | Remy              |       |          |                            |
|                        | 4 | 4,044,143     | Aug. 23, 1977  | Remy              |       |          |                            |
|                        | 5 | 4,198,421     | Apr. 15, 1980  | Cherkofsky et al. |       |          |                            |
|                        | 6 | 5,917,057     | June 29, 1999  | Hamer et al.      |       |          |                            |
| Continue on page _____ |   |               |                |                   |       |          |                            |

  

| FOREIGN PATENT DOCUMENTS |    |                 |                  |         |       |          |                      |
|--------------------------|----|-----------------|------------------|---------|-------|----------|----------------------|
|                          |    | Document Number | Publication Date | Country | Class | Subclass | Translation Yes   No |
|                          | 7  | CA 967,573      | May 13, 1975     | CANADA  |       |          |                      |
|                          | 8  | WO 97/38991     | Oct. 23, 1997    | WIPO    |       |          |                      |
|                          | 9  | WO 99/00355     | Jan. 7, 1999     | WIPO    |       |          |                      |
|                          | 10 | WO 01/87890     | Nov. 22, 2001    | WIPO    |       |          |                      |
|                          | 11 | WO 03/097649    | Nov. 27, 2003    | WIPO    |       |          |                      |
|                          | 12 | WO 03/099823    | Dec. 4, 2003     | WIPO    |       |          |                      |
|                          | 13 | HR 20000310     | Feb. 28, 2002    | CROATIA |       |          | X                    |
|                          | 14 | HR 20020453     | May 23, 2002     | CROATIA |       |          | X                    |
| Continue on page _____   |    |                 |                  |         |       |          |                      |

  

| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) |  |
|--|--|
| 15   | Ackermann L., Harvima I.T. "Mast cells of psoriatic and atopic dermatitis skin are positive for TNF- $\alpha$ and their degranulation is associated with expression of ICAM-1 in the epidermis." Arch. Dermatol. Res. 1998, 290:353-359.                               |
| 16   | Aderka, D. "Role of tumor necrosis factor in the pathogenesis of intravascular coagulopathy of sepsis: potential new therapeutic implications." Isr. J. Med. Sci., 1991, 27:52-60.   |
| 17   | Arrieta O, et al. "Protective effect of pentoxifylline plus thalidomide against septic shock in mice." Int. J. Exp. Pathol. 1999, 80(1):11-16.   |
| 18   | Badger A.M. et al. "Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock." Circ. Shock 1994 44(4):188-195.  |
| 19   | Badger et al. "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function." J. Pharmac. Env. Therap., 1996, 279(3):1453-1461. |
| 20   | Becker et al. "Photochemistry of the Anthracene Chromophore: Novel Isomerization of 1-(9-Anthryl)-2-Benzoethylenes." Tetrahedron Lett., 1985, 26(12):1589-1592.  |
| 21   | Bissonnette E. Y. et al. "Inhibition of tumour necrosis factor- $\alpha$ (TNF- $\alpha$ ) release from mast cells by the anti-inflammatory drugs, sodium cromoglycate and nedocromil sodium." Clin. Exp. Immunol. 1995, 102:78-84.                                     |
| 22   | Bresnihan. "Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in rheumatoid arthritis (RA): results of randomized double-blind, placebo-controlled multicenter trial." Arthritis Rheum., 1996, 39:73.                                      |
| 23   | Cagniant. C.R. Hebd. Sciences Acad. Sci., 1976, 283:683-686  |
| 24   | Carswell et al. "An endotoxin-induced serum factor that causes necrosis of tumors." Proc. Natl. Acad. Sci. U.S.A., 1975, 72:3666-3670.   |
| 25   | Chapman P.T. et al. "Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1." Arthritis Rheum., 1997, 40:955-965.                             |

|    |  |
|----|--|
| 26 | Cheung A. T. et al. "An in vivo model for elucidation of the mechanism of tumor necrosis factor- $\alpha$ (TNF- $\alpha$ )-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF- $\alpha$ ." <i>Endocrinology</i> , 1998, 139:4928-4935.   |
| 27 | Collier et al. "The abdominal constriction response and its suppression by analgesic drugs in the mouse." <i>Br. J. Pharmacol. Chemother.</i> , 1968, 32:295-310   |
| 28 | Corral L., et al. "Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That are Potent Inhibitors of TNF- $\alpha$ ." <i>The Journal of Immunology</i> 1999, 163:380-386.  |
| 29 | Dibbs Z, et al. "Cytokines in heart failure: pathogenetic mechanisms and potential treatment." <i>Proc. Assoc. Am. Physicians</i> , 1999, 111:423-428.   |
| 30 | Di Francia M. et al. "Tumor necrosis factor- $\alpha$ levels and weight loss in chronic obstructive pulmonary disease." <i>Am. J. Respir. Crit. Care Med.</i> 1994, 150:1453-1455.   |
| 31 | Dinarello. "An update on human interleukin-1: From molecular biology to clinical relevance." <i>J. Clinical Immunology</i> , 1985, 5:287.  |
| 32 | Dinarello. "Interleukin-1." <i>Rev. Infect. Disease</i> , 1984, 6(1):51-95.  |
| 33 | Duong D.J. et al. "American experience with lowdose thalidomide therapy for severe cutaneous lupus erythematosus." <i>Arch. Dermatol.</i> 1999 135 (9):1079-1087.  |
| 34 | Egido J. et al. "Role of tumor necrosis factor- $\alpha$ in the pathogenesis of glomerular diseases." <i>Kidney Int. Suppl.</i> 1993, 39:59-64.  |
| 35 | Elliott et al. "Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor $\alpha$ (cA2) versus placebo in rheumatoid arthritis." <i>The Lancet</i> , 1994, 344:1105-1110.   |
| 36 | M. Feldman et al. "Role of Cytokines in Rheumatoid Arthritis." <i>Annu. Rev. Immunol.</i> 1996 14:397-440.   |
| 37 | Fukawa et al. "A method for evaluating analgesic agents in rats." <i>J. Pharmacol. Meth.</i> , 1980, 4:251-259.  |
| 38 | Gauldie J. et al. "Cytokines and pulmonary fibrosis." <i>Thorax</i> , 1993, 48:931-935.  |
| 39 | Georgopoulos et al. "Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice." <i>J. Inflamm.</i> , 1996, 46:86-97.  |
| 40 | Gruschwitz, M., et al. "In situ Expression and Serum Levels of Tumor Necrosis Factor- $\alpha$ Receptors in Patients with Early Stages of Systemic Sclerosis." <i>Journal Rheumatology</i> 1997; 24:1936-43.   |
| 41 | Heilig, B. et al. "Elevated TNF Receptor Plasma Concentrations in Patients with Rheumatoid Arthritis." <i>Clinical Investigation</i> 1992; 70:22-27.   |
| 42 | Heilig B et al. "[Expression of TNF receptors in rheumatoid arthritis and ankylosing spondylitis]." [Article in German]. <i>Z Rheumatol.</i> 1993 Nov-Dec; 52(6):383-9.  |
| 43 | Hotamisligil G.S., Spiegelman B.M. "Tumor necrosis factor $\alpha$ : a key component of the obesity-diabetes link." <i>Diabetes</i> , 1994, 43:1271-1278.  |
| 44 | Iyer and Gopalachari. "Studies in Potential Antifertility Agents: Part VII - Synthesis of Dialkylaminoethul Derivatives of 2,4,5-Triphenylpyrroles & 2,4,5-Triphenylfurans." <i>Indian J. Chem.</i> , 1973, 11:1260-1262.  |
| 45 | Jones et al. "Anti-estrogens. 2. Structure-activity studies in a series of 3-aryl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (LY156758), a markedly effective estrogen antagonist with only minimal intrinsic estrogenicity." <i>J. Med. Chem.</i> , 1984, 27:1057-1066. |
| 46 | Kapadia S. et al. "The role of cytokines in the failing human heart." <i>Cardiol. Clin.</i> , 1998, 16:645-656.  |
| 47 | King, F.D. "Biososteres, Conformational Restriction, and Pro-Drugs - Case History: An Example of a Conformational Restriction Approach." <i>Med. Chem.: Principle and Practice</i> (1994) p. 206-208.  |
| 48 | Kefer, et al. "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis." <i>EMBO J.</i> , 1991, 10:4025-4031.   |
| 49 | Kluth D.C., Rees A.J. "Inhibiting inflammatory cytokines." <i>Semin. Nephrol.</i> 1996, 16:576-582.  |
| 50 | Kopicova et al. "Potential Tetracyclic Neuroleptics: 12-(4-methylpiperazino)benzo[b]naphtho[2,3-f]thiepin and its 12,13-dihydro Derivative." <i>Collect. Czech. Chem. Commun.</i> , 1975, 40:1960-1965.  |
| 51 | Kopicova and Protiva. "Synthesis of 7-(4-methylpiperazino)-7,8-dihydrobenzo[b]naphtho[2,1-f]thiepin and of Related Compounds." <i>Collect. Czech. Chem. Commun.</i> , 1974, 39:3147-3152.  |
| 52 | Krakauer T, Stiles BG. "Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release." <i>Clin Diagn Lab Immunol.</i> 1999 Jul 6(4):594-8.  |
| 53 | Liedtke W. "Effective Treatment of Models of Multiple Sclerosis by Matrix Metalloproteinase Inhibitors." <i>An. of Neurology</i> , 1998, Vol. 44: 35-46.   |
| 54 | Liu J.Y. et al. "TNF- $\alpha$ receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers." <i>Am. J. Pathol.</i> , 1998, 153:1839-1847.  |
| 55 | Maini R.N, Taylor P.C. "Anti-Cytokine Therapy for Rheumatoid Arthritis." <i>Annu. Rev. Med.</i> 2000 51:207-229.   |
| 56 | Martel-Pelletier J, Alaaeddine N. Pelletier JP. "Cytokines and their role in the pathophysiology of osteoarthritis." <i>Front Biosci.</i> 1999 4:D694-703.   |
| 57 | Mattioli and Ghia. "Omega-dialkylaminoalkyl ethers of phenyl-(5-substituted 1-phenyl-1H-pyrazol-4-yl)methanols with analgesic and anti-inflammatory activity." <i>J. Heterocyclic Chem.</i> , 1997, 34:963-968.  |

|    |   |
|----|---|
| 58 | Matsukawa A, et al. "Analysis of the Cytokine Network Among Tumor Necrosis Factor $\alpha$ , Interleukin-1 $\beta$ , Interleukin-8 and Interleukin-1 Receptor Antagonist in Monosodium Urate Crystal-Induced Rabbit Arthritis." <i>Lab Invest</i> 1998; 78:559-569. |
| 59 | McHugh et al. "Preparation of 8H-Furo[3,4-d]dibenz[b,f]azepine. A Novel Heterocyclic Ring System." <i>J. Heterocycl. Chem.</i> , 1990, 27:1839-42.  |
| 60 | Mori et al. "Photochemical reactions of anthracene-napthalene bichromophoric systems linked by a three-carbon chain." <i>J. Chem. Soc., Perkin Trans. 2</i> , 1996, 1:113-119.  |
| 61 | Mori et al. "Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice." <i>J. Immunol.</i> , 1996, 157:3178-3182.  |
| 62 | Noguchi, M., et al. "Secretion Imbalance between Tumor Necrosis Factor and its inhibitor in inflammatory bowel disease." <i>Gut</i> 1998, 43:203-209.   |
| 63 | Nyiondi-Bonguen et al. "[4+2] - Cycloadditions of 3-Amino-4-imino-4H-thieno[3,4-c][1]benzopyran with some Selected Dienophiles." <i>J. Chem Soc., Perkin Trans. 1</i> , 1994, 15:2191-2195.   |
| 64 | Odeh M. "Role of Cytokines in Rheumatoid Arthritis." <i>Drugs News Perspect. II</i> (6) 1998, 331-341.  |
| 65 | Oliver S., et al. "The Effect of Thalidomide and 2 Analogs on Collagen Induced Arthritis." <i>Journal of Rheumatology</i> 1998; 25:964-9.   |
| 66 | Peleman R.A., Kips J.C., Pauwels R.A. "Therapeutic activities of theophylline in chronic obstructive pulmonary disease." <i>Clin. Exp. Allergy</i> 1998 28 Supp. 1:33-56.   |
| 67 | Pfeffer et al. "Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection." <i>Cell</i> , 1993, 73:457-467.  |
| 68 | Piguet P.F. et al. "Expression and localization of tumor necrosis factor- $\alpha$ and its mRNA in idiopathic pulmonary fibrosis." <i>Am. J. Pathol.</i> 1993, 143:651-655.   |
| 69 | Piguet P.F., Vesin C. "Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice." <i>Eur. Respir. J.</i> , 1994, 7:515-518.   |
| 70 | Reimund J. "In vitro effects of oxpentifylline on Inflammatory Cytokine Release in Patients with Inflammatory Bowel Disease." <i>Gut</i> 1997, 40:475-480.  |
| 71 | Ross S., et al. "Suppression of TNF $\alpha$ Expression, Inhibition of TH1 Activity and Amelioration of Collagen-Induced Arthritis by Rolipram." <i>Journal of Immunology</i> , 1997, 159:6253-6259.  |
| 72 | Rutgeerts P. et al. "Efficacy and Safety of Retreatment with Anti-Tumor Necrosis Factor Antibody (Infliximab) to Maintain Remission in Crohn's Disease." <i>Gastroenterology</i> , 1999, 117:761-769.   |
| 73 | Sandborn W. and Hanauer S. "Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease; A review of Agents, Pharmacology, Clinical Results and Safety." <i>Inflammatory Bowel Diseases</i> 1999, 5(2):119-133.  |
| 74 | Saricaoglu H. et al. "Prevention of nickel-induced allergic contact reactions with pentoxifylline." <i>Contact Dermatitis</i> 1998, 39(5):244-247.  |
| 75 | Sasayama S. et al. "New insights into the pathophysiological role for cytokines in heart failure." <i>Cardiovasc Res.</i> 1999, 42:557-564.   |
| 76 | Schmidt H. et al. "Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats." <i>J. Surg. Res.</i> 1996 63(1):143-146.  |
| 77 | Schweizer et al. "Combined automated writhing/motility test for testing analgesics." <i>Agents and Actions</i> , 1988, 23:29-31.  |
| 78 | Shire, MG and Muller GW. "TNF- $\alpha$ inhibitors and rheumatoid arthritis." <i>Exp. Opin. Ther. Patents</i> . 1998 8(5): 531-544.   |
| 79 | Sürling D. I. Semin. "Thalidomide and its impact in dermatology." <i>Cutan. Med. Surg.</i> 1998 17(4):231-242.  |
| 80 | Sykes A.P. et al. "The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a Eritrobenzenesulphonic acid rat model of inflammatory bowel disease." <i>Aliment Pharmacol Ther.</i> 1999, 13:1535-1542.                                    |
| 81 | Taylor R. Multiple Sclerosis: A Rehabilitative Approach, 1998, 9, 3, 525-536. "Immunologic Aspects of Multiple Sclerosis."  |
| 82 | Tochtermann et al. Ein neuer Zugang zu chiralen Tribenzocycloheptarien-(Tribenzo-[a.c.]cyclohepten-) und Tribenzo[b.d.]thiiepin-S,S-dioxid-Derivaten." <i>Chem. Ber.</i> , 1968, 101:3122-3137.   |
| 83 | Tomizawa S. et al. "TNF inhibitory activity in the urine of chronic renal failure patients with glomerulonephritis." <i>Nephron</i> . 1993, 63:111-112.   |
| 84 | Tsuji et al. "Studies on Anti-Inflammatory Agents. VI. Synthesis and Pharmacological Properties of 2,3-Diarythiophenes." <i>Chem. Pharm. Bull.</i> , 1998, 46(2):279-286.   |
| 85 | Ueda et al. "The Synthesis of 10-(4-Methylpiperazino)dibenzo[b,f]thiiepin and Related Compunds. Neurotropic and Psychotropic Agents." <i>Chem. Pharm. Bull.</i> , 1975, 23(10):2223-2231.   |
| 86 | Van Assche and Rutgeerts. "Anti-TNF agents in Crohn's disease." <i>Exp. Opin. Invest. Drugs</i> , 2000, 9:103-111.  |
| 87 | Vippagunta, S.R. et al. "Crystalline solids." <i>Advanced Drug Delivery Reviews</i> , 2001, 48(1):3-26.   |
| 88 | Wermuth et al. "Molecular Variations Based on Isosteric Replacements." <i>Practice of Medicinal Chemistry</i> , 1996, pages 203-237.  |
| 89 | Westacott C.I. et al. "Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis." <i>Osteoarthritis Cartilage</i> 2000 8(3):213-221.   |

|   |  |
|---|--|
| 90  | Wim B van den Berg, Ph.D. "Anti-Cytokine Therapy in Chronic Destructive Arthritis." Arthritis Res 2001, 3:18-26.   |
| 91  | Postmarketing Adverse Event Data for TNF-alpha Antagonists (October 23, 2001). Stephen A. Paget, MD<br>< <a href="http://rheumatology.hss.edu/phys/specialreports/pagettnf.asp">http://rheumatology.hss.edu/phys/specialreports/pagettnf.asp</a> > |
| 92  | Green (Using TNF alpha technology to treat rheumatoid arthritis) Article (July/August 2004).<br>< <a href="http://rheumatology.hss.edu/phys/specialreports/pagettnf.asp">http://rheumatology.hss.edu/phys/specialreports/pagettnf.asp</a> >        |
| 93  | Centocor products (08/11/2004) < <a href="http://www.centocor.com/cgi-bin/site/products/prod_remicade.cgi">http://www.centocor.com/cgi-bin/site/products/prod_remicade.cgi</a> is cited for the statement that>                                    |
| 94  | "News & Notices: <a href="http://www.psoriasis.org/enbrel_approval_jan02.htm">http://www.psoriasis.org/enbrel_approval_jan02.htm</a> (7/30/2002).  |
| Continue on page  |  |
| EXAMINER  | DATE CONSIDERED  |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. |  |